

**Table 5. SGX393-nilotinib combination mutagenesis study**

		Total wells (sequenced clones)	Mutation recovered	Number of occurrences	Frequency (%)	Mutations recovered (by residue)	Frequency (by residue) (%)
SGX393 + nilotinib combinations							
[SGX393]	[nilotinib]						
240nM	250nM	96 (n=3)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			Y253H	2	66.7	253	66.7
			E255V	1	33.3	255	33.3
240nM	500nM	96 (n=1)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	1	100.0	248	100.0
240nM	1000nM	96 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
240nM	2000nM	96 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
480nM	250nM	288 (n=1)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			E255V	1	100.0	255	100.0
480nM	500nM	288 (n=5)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	5	100.0	248	100.0
480nM	1000nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
480nM	2000nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
960nM	250nM	288 (n=2)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	2	100.0	248	100.0
960nM	500nM	288 (n=2)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	1	50.0	248	50.0
			E255V	1	50.0	255	50.0
960nM	1000nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
960nM	2000nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	250nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	500nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	1000nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
1920nM	2000nM	288 (n=0)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0